OPTiM (ClinicalTrials.gov NCT00769704) was a randomized phase III trial that compared T-VEC and GM-CSF in patients who had histologically confirmed unresectable stage IIIB/C/IV melanoma with at least one cutaneous, subcutaneous, or nodal lesion [13,54]. Here, CSF2 is linked to melanoma.